Accessibility Menu
Renalytix Plc logo

Renalytix Plc(LSE) RENX

Current Price£0.03
Market Cap£11.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-98%
5 Year-100%
1 Year-63%
1 Month+42%
Renalytix Plc last closing stock price
MetricPriceDate
Last closeGBX 2.702026-07-22
Renalytix Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.89%GBX 2.652026-07-15
1 month+42.11%GBX 1.902026-06-22
3 month+45.95%GBX 1.852026-04-23
Year to date-54.24%GBX 5.902025-12-31
1 year-62.76%GBX 7.252025-07-22
3 year-97.92%GBX 130.002023-07-21
5 year-99.76%GBX 1,105.002021-07-23
Since inception-97.71%GBX 1.202018-11-06

Renalytix Plc Financials at a Glance

Market Cap

£11.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.85M

Net Income (TTM)

-$16.71M

EPS (TTM)

£0.00

P/E Ratio

-0.19

Dividend

£0.00

Beta (Volatility)

0.17 (Low)

Price

£0.03

Volume

153,155

Open

£0.03

Previous Close

£0.03

Daily Range

£0.03 - £0.03

52-Week Range

£0.02 - £0.16

Estimated Earnings Date

Nov 3, 2026

RENX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Renalytix Plc

Renalytix Plc specializes in developing advanced in vitro diagnostic solutions for kidney diseases, utilizing artificial intelligence. The company's flagship product, KidneyIntelX, provides individualized risk scores to enhance kidney disease diagnosis and management.

Products and Services
  • KidneyIntelX: AI-driven diagnostic platform for kidney disease
  • Partnerships for biomarker-based products with leading health institutions
  • Laboratory assays for SARS-CoV-2 antibody detection
Growth Outlook
  • Partnership with Mount Sinai Health System enhances market reach
  • Collaborations with Atrium Health aim to improve kidney health management
  • Focus on innovative AI applications positions company for future growth
Financial Highlights
  • Recent quarterly revenue of 729,000 shows upward trend
  • Trailing twelve months (TTM) revenue of 2.4 million indicates growth potential
  • Cash reserves increased to 9.2 million, supporting operational stability
Renalytix Plc is positioned at the intersection of healthcare and technology, focusing on kidney disease diagnostics. The innovative KidneyIntelX platform leverages AI to synthesize diverse data streams, providing healthcare professionals with critical insights for patient management. The company's strategic partnerships with renowned institutions like Mount Sinai and Joslin Diabetes Center enhance its credibility and market presence. Recent financial data indicates a positive trajectory, with increasing revenue and cash reserves, suggesting a solid foundation for future growth. As the demand for advanced diagnostic solutions continues to rise, Renalytix is well-placed to capitalize on emerging opportunities in the healthcare sector.
AI Generated • Jul 4, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

46

CEO

James Renwick McCullough, MBA

Website

renalytix.com

Headquarters

New York City, NY 10036, US

RENX Financials

Key Financial Metrics (TTM)

Gross Margin

6.82%

Operating Margin

-1293.49%

Net Income Margin

-1461.60%

Return on Equity

-631.25%

Return on Capital

-1323.08%

Return on Assets

-419.67%

Earnings Yield

-5.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£11.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

437.02M

Volume

153.16K

Avg. Volume

681.15K

Financials (TTM)

Gross Profit

$1.30M

Operating Income

-$14.63M

EBITDA

-$11.53M

Operating Cash Flow

-$15.73M

Capital Expenditure

-$100.00K

Free Cash Flow

-$15.83M

Cash & ST Invst.

$6.20M

Total Debt

$5.80M

Renalytix Plc Performance Analysis

Renalytix Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 2,234,255N/A
20232023-06-30USD 2,829,16126.6%
20242024-06-30USD 1,826,972-35.4%
20252025-06-30USD 2,318,93626.9%
Renalytix Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-09-30-10.9%
Q22024-12-3139.7%
Q12025-09-30N/A
Q22025-12-31N/A
Renalytix Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -0.47N/A
20232023-06-30USD -0.46-1.3%
20242024-06-30USD -0.33-27.6%
20252025-06-30USD -0.06-82.8%
Renalytix Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-09-3012.7%
Q22024-12-3110.7%
Q12025-09-30N/A
Q22025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$800.00K

+36.5%

Gross Profit

$400.00K

+1011.1%

Gross Margin

50.00%

N/A

Market Cap

£11.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£256.51K

N/A

Employees

46

N/A

Net Income

-$4.05M

+42.7%

EBITDA

$0.00

+100.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$6.20M

+32.5%

Total Debt

$5.80M

-32.0%

Accounts Receivable

$1.30M

+80.1%

Inventory

$300.00K

N/A

Long Term Debt

$5.60M

+29.3%

Short Term Debt

$200.00K

-95.2%

Return on Assets

-4.20%

N/A

Return on Invested Capital

8.40%

N/A

Free Cash Flow

-$2.75M

+64.9%

Operating Cash Flow

-$2.70M

+65.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COG.LCambridge Cognition Holdings Plc
£0.33+1.23%
IHC.LInspiration Healthcare Group plc
£0.19+2.16%
FDBK.LFeedback plc
£0.06-0.80%
NCYT.LNovacyt S.A.
£0.38-0.72%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About RENX

What is the current price of Renalytix Plc?

Renalytix Plc is trading at £0.03 per share.

What is the 52-week range for Renalytix Plc?

Over the past 52 weeks, Renalytix Plc has traded between £0.02 and £0.16.

How much debt does Renalytix Plc have?

As of the most recent reporting period, Renalytix Plc reported total debt of $6.55M.

How much cash does Renalytix Plc have on hand?

Renalytix Plc reported $7.35M in cash and cash equivalents in its most recent financial results.

What is Renalytix Plc’s dividend yield?

Renalytix Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services